Combination therapies for advanced prostate and other epithelial cancers. 

1) The Stoyanova lab is utilizing proteomic approaches to identify new druggable proteins upon treatment with therapeutic agents.

2) By defining new druggable targets, throughout treatment course, the lab designs combination and sequential therapies with multiple experimental agents with FDA-approved agents. 

3) The goal of the sequential and combination therapies is to improve therapeutic responses and efficacy, which ultimately improves patient outcome and cancer-associated mortalities.